Category Archives: Business and Investments

Latest From Business and Investments

BIO White Paper Highlights Key Industry Legislation and its Impact on the Industry

Emerging-Companies115x76

Innovative biotech companies at all stages of the development process are working toward next generation technologies to heal, fuel, and feed the world. In an effort to highlight promising policy legislation and its impact on the biotech sector, BIO has authored the following white paper: The Future Policy Landscape for Emerging Biotechnology Companies. Many research-intensive companies rely on private investment to support their groundbreaking R&D. Therefore, favorable legislation such as the JOBS Act is essential Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

What’s Behind the Biotech IPO Boom?

BIOtech-stocks

Everyone knows that it’s been a knock-out year for the biotech sector in the public markets, which includes a large and well-performing IPO class. So far in 2013, 39 US-based companies have gone public, five European-based companies, and one Canadian company. Of these 45 IPOs, 42 companies have gone public on US stock exchanges. That’s over double the amount we saw in 2012. This year’s IPOs have also been successful at raising the amount of money Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Fewer Small Public Biotechs Today

Fig2-size-2008-vs-2013-115x76

A lot can happen in six years. The number of active biotech companies currently trading on US exchanges is now only 300. At the start of 2008, there were almost 400 active companies.   The net decrease in the number of active companies since 2008 is 24%. Had it not been for all the IPO activity we have seen this year, the decrease would have been substantially more. In fact, only 55% of the original Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Emerging Company Policy Deconstructed: Fostering Innovation Act (H.R. 2629)

scientists115x76

In a nutshell: Representative Michael Fitzpatrick (R-PA) introduced H.R. 2629, the Fostering Innovation Act, to update SEC filing status classifications for public companies and help ease regulatory burdens on emerging companies and reduce the bureaucratic hurdles and red tape that lengthen the time to bring cures from discovery to patient. Why you should care: SEC Rule 12b-2 establishes three classifications for public companies to determine their filing status, which include large accelerated filers (companies with Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

The Value of Partnering Continues to be a Draw for BIO Events

Last month’s BIO Convention in China saw 700 partnering meetings between executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia. These meetings allowed industry executives to meet and explore business opportunities with China’s emerging biotech sector. One company in particular, SciClone Pharmaceuticals, invited BioWorld to tag along for the day and get an insider’s look at what a full day of partnering entails. To better understand the full scope of participating in these partnering meetings, read Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,